Vol 82, No 11 (2024)
Clinical vignette
Published online: 2024-09-05
Heart failure in a young adult: Cardiomyopathy or much more?
Abstract
Not available
References
- Aimo A, Merlo M, Porcari A, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022; 24(12): 2342–2351.
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021; 42(16): 1554–1568.
- Grzybowski J, Podolec P, Holcman K, et al. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society. Kardiol Pol. 2023; 81(11): 1167–1185.
- Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023; 44(37): 3503–3626.
- Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. Lancet. 2017; 389(10068): 519–527.
